Donor-specific antibodies following liver and intestinal transplantation: Clinical significance, pathogenesis and recommendations

References

• Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003;3(6):665–673.
   PubMed Web of Science ®Google Scholar
• Kannabhiran D, Lee J, Schwartz JE. Characteristics of circulating donor human leukocyte antigen-specific immunoglobulin G antibodies predictive of acute antibody-mediated rejection and kidney allograft failure. Transplantation 2015;99(6):1156–1164. doi: 10.1097/TP.0000000000000511.
   PubMed Web of Science ®Google Scholar
• Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012;23(12):2061–2071. doi: 10.1681/ASN.2012070664.
   PubMed Web of Science ®Google Scholar
• Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009;9(11):2520–2531. doi: 10.1111/j.1600-6143.2009.02799.x.
   PubMed Web of Science ®Google Scholar
• Kaczmarek I, Deutsch MA, Kauke T, et al. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp Clin Transplant 2008;6:229–235.
   PubMed Web of Science ®Google Scholar
• Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011;11(2):312–319. doi: 10.1111/j.1600-6143.2010.03383.x.
   PubMed Web of Science ®Google Scholar
• Morrell MR, Pilewski JM, Gries CJ, et al. De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation. J Heart Lung Transplant 2014;33:1288–1294. doi: 10.1016/j.healun.2014.07.018.
   PubMed Web of Science ®Google Scholar
• Demetris AJ, Zeevi A, O’Leary JG. ABO-compatible liver allograft antibody-mediated rejection: an update. Curr Opin Organ Transplant 2015;20(3):314–324. doi: 10.1097/MOT.0000000000000194.
   PubMed Web of Science ®Google Scholar
• Wozniak LJ, Naini BV, Hickey MJ, et al.. Acute antibody-mediated rejection in ABO-compatible pediatric liver transplant recipients: case series and review of the literature. Pediatr Transplant 2017;21(1). doi: 10.1111/petr.12791.
   PubMedGoogle Scholar
• O’Leary JG, Cai J, Freeman R, et al. Proposed diagnostic criteria for chronic antibody-mediated rejection in liver allografts. Am J Transplant 2016;16(2):603–14. doi: 10.1111/ajt.13476.
   Google Scholar
• Demetris AJ, Bellamy C, Hübscher SG, et al. 2016 Comprehensive update of the Banff Working Group on liver allograft pathology: introduction of antibody-mediated rejection. Am J Transplant 2016;16(10):2816–2835. doi: 10.1111/ajt.13909
   Web of Science ®Google Scholar
• Kasahara M, Kiuchi T, Takakura K, et al. Postoperative flow cytometry crossmatch in living donor liver transplantation: clinical significance of humoral immunity in acute rejection. Transplantation 1999;67(4):568–575. doi: 10.1097/00007890-199902270-00014.
   PubMed Web of Science ®Google Scholar
• Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011;11(3):500–510. doi: 10.1111/j.1600-6143.2010.03414.x.
   PubMed Web of Science ®Google Scholar
• Kaneku H, O’Leary JG, Taniguchi M, et al. Donor-specific HLA antibodies of IgG3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012;18(8):984–92. doi: 10.1002/lt.23451.
   PubMed Web of Science ®Google Scholar
• Castillo-Rama M, Castro MJ, Bernardo I, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl 2008;14(4):554–562. doi: 10.1002/lt.21408.
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Kaneku H, Banuelos N, et al. Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant 2015;15(4):1003–1013. doi: 10.1111/ajt.13153.
   PubMed Web of Science ®Google Scholar
• Vandevoorde K, Ducreux S, Bosch A, et al. Prevalence, risk factors, and impact of donor-specific alloantibodies after adult liver transplantation. Liver Transpl 2018;24(8):1091–1100. doi: 10.1002/lt.25177.
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Kaneku H, Jennings LW, et al. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013;19(9):973–980. doi: 10.1002/lt.23687.
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011;11(9):1868–1876. doi: 10.1111/j.1600-6143.2011.03593.x.
   PubMed Web of Science ®Google Scholar
• Fontana M, Moradpour D, Aubert V, et al. Prevalence of anti-HLA antibodies after liver transplantation. Transpl Int 2009;23(8):858–859. doi: 10.1111/j.1432-2277.2009.01022.x.
   PubMed Web of Science ®Google Scholar
• Grabhorn E, Binder TMC, Obrecht D, et al. Long-term clinical relevance of de novo donor-specific antibodies after pediatric liver transplantation. Transplantation 2015;99(9):1876–1881. doi: 10.1097/TP.0000000000000638.
   PubMed Web of Science ®Google Scholar
• Couchonnal E, Rivet C, Ducreux S, et al. Deleterious impact of C3d-binding donor-specific anti-HLA antibodies after pediatric liver transplantation. Transplant Immunol 2017;45:8–14. doi: 10.1016/j.trim.2017.08.001.
   PubMed Web of Science ®Google Scholar
• Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific HLA antibodies in pediatric late liver allografts. Liver Transpl 2012;18(11):1333–42. doi: 10.1002/lt.23534.
   PubMed Web of Science ®Google Scholar
• Del Bello A, Congy-Jolivet N, Muscari F, et al. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant 2014;14(4):867–875. doi: 10.1111/ajt.12651.
   PubMed Web of Science ®Google Scholar
• Ueno T, Zenitani M, Yamanaka H, et al. Impact of donor-specific antibodies on graft fibrosis after pediatric living donor liver transplantation for biliary atresia. Transplant Proc 2016;48(4):1095–1099. doi: 10.1016/j.transproceed.2016.02.011.
   PubMed Web of Science ®Google Scholar
• Tokodai K, Miyagi S, Nakanishi C, et al. Association of post-transplant donor-specific HLA antibody with liver graft fibrosis during long-term follow-up after pediatric liver transplantation. Pediatr Transplant 2018;22(3):e13169. doi: 10.1111/petr.13169.
   PubMed Web of Science ®Google Scholar
• Ohe H, Uchida Y, Yoshizawa A, et al. Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal. Transplantation 2014;98(10):1105–1111. doi: 10.1097/TP.0000000000000185.
   PubMed Web of Science ®Google Scholar
• Markiewicz-Kijewska M, Kaliciński P, Kluge P, et al. Immunological factors and liver fibrosis in pediatric liver transplant recipients. Ann Transplant 2015;20:279–284.
   PubMed Web of Science ®Google Scholar
• Wozniak LJ, Hickey MJ, Venick RS, et al. Donor-specific HLA antibodies are associated with late allograft dysfunction after pediatric liver transplantation. Transplantation 2015;99(7):1416–1422. doi: 10.1097/TP.0000000000000796.
   PubMed Web of Science ®Google Scholar
• Kivela JM, Kosola S, Peräsaari J, et al. Donor-specific antibodies after pediatric liver transplantation: a cross-sectional study of 50 patients. Transpl Int 2016;29(4):494–505.
   PubMed Web of Science ®Google Scholar
• Kaneku H, O’Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013;13(6):1541–8. doi: 10.1002/ajt.12212.
   PubMedGoogle Scholar
• O’Leary JG, Demetris AJ, Philippe A, et al. Non-HLA antibodies impact on C4d staining, stellate cell activation and fibrosis in liver allografts. Transplantation 2017;101(10):2399–2409. doi: 10.1097/TP.0000000000001853.
   Web of Science ®Google Scholar
• Al-Sibae MR, Koffron AJ, Raofi V. Does a positive pretransplant crossmatch affect long-term outcome in liver transplantation? Transplantation 2011;91(3):261–262. doi: 10.1097/TP.0b013e318204758c.
   PubMed Web of Science ®Google Scholar
• den Dulk AC, Shi X, Verhoeven CJ, et al. Donor-specific anti-HLA antibodies are not associated with nonanastomotic biliary strictures but both are independent risk factors for graft loss after liver transplantation. Clin Transplant 2018;32(2) doi: 10.1111/ctr.13163.
   PubMed Web of Science ®Google Scholar
• Taner T, Gandhi MJ, Sanderson SO, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012;12(6):1504–10. doi: 10.1111/j.1600-6143.2012.03995.x.
   PubMedGoogle Scholar
• Barcelos S, Dias AS, Forgiarini Jr LA, et al. [Liver transplantation: effects in pulmonary capacity, functional condition and quality of life]. Arq Gastroenterol 2008;45(3):186–191.
   PubMedGoogle Scholar
• Waki K, Sugawara Y, Mizuta K, et al. Predicting operational tolerance in pediatric living-donor liver transplantation by absence of HLA antibodies. Transplantation 2013;95(1):177–183. doi: 10.1097/TP.0b013e3182782fef.
   PubMed Web of Science ®Google Scholar
• Girnita A, Mazariegos GV, Castellaneta A, et al. Liver transplant recipients weaned off immunosuppression lack circulating donor-specific antibodies. Hum Immunol 2010;71(3):274–276. doi: 10.1016/j.humimm.2009.12.002.
   PubMed Web of Science ®Google Scholar
• Del Bello A, Congy-Jolivet N, Danjoux M, et al. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients. Transpl Int 2015;28(12):1371–1382. doi: 10.1111/tri.12654.
   PubMed Web of Science ®Google Scholar
• Del Bello A, Congy-Jolivet N, Danjoux M, et al. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018;24(16):1795–1802. doi: 10.3748/wjg.v24.i16.1795.
   PubMed Web of Science ®Google Scholar
• Tokodai K, Kawagishi N, Miyagi S, et al. The significance of screening for HLA antibodies in the long-term follow-up of pediatric liver transplant recipients. Transplant Proc 2016;48(4):1139–1141. doi: 10.1016/j.transproceed.2015.12.081.
   PubMed Web of Science ®Google Scholar
• Tokodai K, Miyagi S, Nakanishi C, et al. Effect of recipient age at liver transplantation on prevalence of post-transplant donor-specific HLA antibody. Ann Transplant 2017;22:333–337.
   PubMed Web of Science ®Google Scholar
• Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012;307(3):283–293. doi: 10.1001/jama.2011.2014.
   PubMed Web of Science ®Google Scholar
• Feng S, Demetris AJ, Spain KM, et al. Five-year histological and serological follow-up of operationally tolerant pediatric liver transplant recipients enrolled in WISP-R. Hepatology 2017;65(2):647–660. doi: 10.1002/hep.28681.
   Web of Science ®Google Scholar
• Stegall MD, Chedid MF, Cornell LD. The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol 2012;8(11):670–678. doi: 10.1038/nrneph.2012.212.
   PubMed Web of Science ®Google Scholar
• Collins AM, Jackson KJ. A temporal model of human IgE and IgG antibody function. Front Immunol 2013;4:235. doi: 10.3389/fimmu.2013.00235.
   PubMed Web of Science ®Google Scholar
• Levitsky J, Kaneku H, Jie C, et al. Donor-specific HLA antibodies in living versus deceased donor liver transplant recipients. Am J Transplant 2016;16(8):2437–2444. doi: 10.1111/ajt.13757.
   PubMed Web of Science ®Google Scholar
• Angaswamy N, Tiriveedhi V, Sarma NJ, et al. Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection. Hum Immunol 2013;74(11):1478–1485. doi: 10.1016/j.humimm.2013.07.002.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Reed EF. The importance of non-HLA antibodies in transplantation. Nat Rev Nephrol 2016;12(8):484–495. doi: 10.1038/nrneph.2016.88.
   PubMed Web of Science ®Google Scholar
• Paterno F, Shiller M, Tillery G, et al. Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 2012;12(9):2526–2531. doi: 10.1111/j.1600-6143.2012.04126.x.
   PubMed Web of Science ®Google Scholar
• Lee C-F, Eldeen FZ, Chan K-M, et al. Bortezomib is effective to treat acute humoral rejection after liver transplantation. Transplant Proc 2012;44(2):529–531. doi: 10.1016/j.transproceed.2012.01.051.
   PubMed Web of Science ®Google Scholar
• Ratner LE, Phelan D, Brunt EM, et al. Probable antibody-mediated failure of two sequential ABO-compatible hepatic allografts in a single recipient. Transplantation 1993;55(4):814–819. doi: 10.1097/00007890-199304000-00025.
   PubMed Web of Science ®Google Scholar
• Rostron A, Carter V, Mutunga M, et al. A case of acute humoral rejection in liver transplantation: successful treatment with plasmapheresis and mycophenolate mofetil. Transpl Int 2005;18(11):1298–1301. doi: 10.1111/j.1432-2277.2005.00200.x.
   PubMed Web of Science ®Google Scholar
• Watson R, Kozlowski T, Nickeleit V, et al. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant 2006;6(12):3022–3029. doi: 10.1111/j.1600-6143.2006.01554.x.
   PubMed Web of Science ®Google Scholar
• Kamar N, Lavayssière L, Muscari F, et al. Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation. World J Gastroenterol 2009;15(27):3426–3430. doi: 10.3748/wjg.15.3426.
   PubMed Web of Science ®Google Scholar
• Chan K-M, Lee C-S, Wu T-J, et al. Clinical perspective of acute humoral rejection after blood type-compatible liver transplantation. Transplantation 2011;91(5):e29–e30. doi: 10.1097/TP.0b013e318208138c.
   PubMed Web of Science ®Google Scholar
• Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011;17(4):357–368. doi: 10.1002/lt.22233.
   PubMed Web of Science ®Google Scholar
• Kheradmand T, Anthony TL, Harland RC, et al. Antibody-mediated rejection in ABO compatible husband to wife living donor liver transplant and review of the literature. Hum Immunol 2014;75(6):578–583. doi: 10.1016/j.humimm.2014.02.010.
   PubMed Web of Science ®Google Scholar
• Starzl TE, Demetris AJ, Todo S, et al. Evidence for hyperacute rejection of human liver grafts: the case of the canary kidneys. Clin Transplant 1989;3:37–45.
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Kaneku H, Demetris AJ, et al. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl 2014;20(2):218–227. doi: 10.1002/lt.23788.
   PubMed Web of Science ®Google Scholar
• Wilson CH, Agarwal K, Talbot D, et al. Late humoral rejection in a compliant ABO-compatible liver transplant recipient. Transplantation 2006;82(7):988–989. doi: 10.1097/01.tp.0000229939.85412.27.
   PubMed Web of Science ®Google Scholar
• Ali S, Ormsby A, Shah V, et al. Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection. Transplant Immunol 2012;26(1):62–69. doi: 10.1016/j.trim.2011.08.005.
   PubMed Web of Science ®Google Scholar
• Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004;4(7):1033–1041. doi: 10.1111/j.1600-6143.2004.00500.x.
   PubMed Web of Science ®Google Scholar
• Hubscher SG. Antibody-mediated rejection in the liver allograft. Curr Opin Organ Transplant 2012;17(3):280–286.
   PubMed Web of Science ®Google Scholar
• Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014;14(2):272–283. doi: 10.1111/ajt.12590.
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Michelle Shiller S, Bellamy C, et al. Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features. Liver Transpl 2014;20(10):1244–1255. doi: 10.1002/lt.23948.
   PubMed Web of Science ®Google Scholar
• Bellamy CO. Complement C4d immunohistochemistry in the assessment of liver allograft biopsy samples: applications and pitfalls. Liver Transpl 2011;17(7):747–750. doi: 10.1002/lt.22323.
   PubMed Web of Science ®Google Scholar
• Markiewicz-Kijewska M, Kaliciński P, Kluge P, et al. Antibody-mediated rejection in pediatric liver transplant recipients. Ann Transplant 2014;19:119–123.
   PubMed Web of Science ®Google Scholar
• Astarcioglu I, Cursio R, Reynes M, et al. Increased risk of antibody-mediated rejection of reduced-size liver allografts. J Surg Res 1999;87(2):258–262. doi: 10.1006/jsre.1999.5734.
   PubMed Web of Science ®Google Scholar
• Guerra MR, Naini BV, Scapa JV, et al. Obliterative portal venopathy: a histopathologic finding associated with chronic antibody-mediated rejection in pediatric liver allografts. Pediatr Transplant 2018;22(2) doi: 10.1111/petr.13124.
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Smith C, Cai J, et al. Chronic AMR in liver transplant: validation of the 1-year cAMR score’s ability to determine long-term outcome. Transplantation 2017;101(9):2062–2070.
   PubMed Web of Science ®Google Scholar
• Grant D, Abu-Elmagd K, Mazariegos G, et al. Intestinal transplant registry report: global activity and trends. Am J Transplant 2015;15(1):210–219. doi: 10.1111/ajt.12979.
   PubMed Web of Science ®Google Scholar
• Smith JM, Skeans MA, Horslen SP, et al. OPTN/SRTR 2013 Annual Data Report: intestine. Am J Transplant 2015;15(S2):1–16. doi: 10.1111/ajt.13198.
   Google Scholar
• Abu-Elmagd KM, Costa G, Bond GJ, et al. Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. Ann Surg 2009;250:567–581.
   PubMed Web of Science ®Google Scholar
• Tsai HL, Island ER, Chang JW, et al. Association between donor-specific antibodies and acute rejection and resolution in small bowel and multivisceral transplantation. Transplantation 2011;92(6):709–715. doi: 10.1097/TP.0b013e318229f752.
   PubMed Web of Science ®Google Scholar
• Abu-Elmagd KM, Wu G, Costa G, et al. Preformed and de novo donor specific antibodies in visceral transplantation: long-term outcome with special reference to the liver. Am J Transplant 2012;12(11):3047–3060. doi: 10.1111/j.1600-6143.2012.04237.x.
   PubMed Web of Science ®Google Scholar
• Gerlach UA, Lachmann N, Sawitzki B, et al. Clinical relevance of the de novo production of anti-HLA antibodies following intestinal and multivisceral transplantation. Transpl Int 2014;27(3):280–289. doi: 10.1111/tri.12250.
   PubMed Web of Science ®Google Scholar
• Kubal C, Mangus R, Saxena R, et al. Prospective monitoring of donor-specific anti-HLA antibodies after intestine/multivisceral transplantation: significance of de novo antibodies. Transplantation 2015;99(8):e49–e56. doi: 10.1097/TP.0000000000000614.
   PubMed Web of Science ®Google Scholar
• Cheng EY, Everly MJ, Kaneku H, et al. Prevalence and clinical impact of donor specific alloantibody among intestinal transplant recipients. Transplantation 2017;101(4):873–882. doi: 10.1097/TP.0000000000001391.
   PubMed Web of Science ®Google Scholar
• Bond G, Reyes J, Mazariegos G, et al. The impact of positive T-cell lymphocytotoxic crossmatch on intestinal allograft rejection and survival. Transplant Proc 2000;32(6):1197–1198. doi: 10.1016/S0041-1345(00)01181-7.
   PubMed Web of Science ®Google Scholar
• Wu T, Abu-Elmagd K, Bond G, et al. A clinicopathologic study of isolated intestinal allografts with preformed IgG lymphocytotoxic antibodies. Hum Pathol 2004;35(11):1332–1339. doi: 10.1016/j.humpath.2004.07.001.
   PubMed Web of Science ®Google Scholar
• Ruiz P, Garcia M, Pappas P, et al. Mucosal vascular alterations in isolated small-bowel allografts: relationship to humoral sensitization. Am J Transplant 2003;3(1):43–49. doi: 10.1034/j.1600-6143.2003.30108.x.
   PubMed Web of Science ®Google Scholar
• Farmer DG, Venick RS, Colangelo J, et al. Pretransplant predictors of survival after intestinal transplantation: analysis of a single-center experience of more than 100 transplants. Transplantation 2010;90(12):1574–1580. doi: 10.1097/TP.0b013e31820000a1.
   PubMed Web of Science ®Google Scholar
• Kato T, Mizutani K, Terasaki P, et al. Association of emergence of HLA antibody and acute rejection in intestinal transplant recipients: a possible evidence of acute humoral sensitization. Transplant Proc 2006;38(6):1735.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Pinto IM, Tzakis AG, Tsai HL, et al. Association between panel reactive antibodies and acute small bowel rejection: analysis of a series of 324 intestinal transplants. Transplant Proc 2010;42(10):4269.
   PubMed Web of Science ®Google Scholar
• Gerlach UA, Lachmann N, Ranucci G, et al. Non-HLA antibodies may accelerate immune responses after intestinal and multivisceral transplantation. Transplantation 2017;101(1):141–149. Jandoi: 10.1097/TP.0000000000001439.
   PubMed Web of Science ®Google Scholar
• Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012;12(5):1157–1167. doi: 10.1111/j.1600-6143.2012.04013.x.
   PubMed Web of Science ®Google Scholar
• Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012;12(2):388–399. doi: 10.1111/j.1600-6143.2011.03840.x.
   PubMed Web of Science ®Google Scholar
• de Serre NP, Canioni D, Lacaille F, et al. Evaluation of C4d deposition and circulating antibody in small bowel transplantation. Am J Transplant 2008;8(6):1290–1296. doi: 10.1111/j.1600-6143.2008.02221.x.
   PubMed Web of Science ®Google Scholar
• Fujiwara S, Wada M, Kudo H, et al. Effectiveness of bortezomib in a patient with acute rejection associated with an elevation of donor-specific HLA antibodies after small-bowel transplantation: case report. Transplant Proc 2016;48:525–527. doi: 10.1016/j.transproceed.2015.09.073.
   PubMed Web of Science ®Google Scholar
• Island ER, Gonzalez-Pinto IM, Tsai HL, et al. Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation. Clin Transplant 2009;465–469.
   Google Scholar
• Fan J, Tryphonopoulos P, Tekin A, et al. Eculizumab salvage therapy for antibody-mediated rejection in a desensitization-resistant intestinal re-transplant patient. Am J Transplant 2015;15(7):1995–2000. doi: 10.1111/ajt.13183.
   PubMed Web of Science ®Google Scholar
• Everly MJ, Terasaki PI, Trivedi HL. Durability of antibody removal following proteasome inhibitor-based therapy. Transplantation 2012;93(6):572–577. doi: 10.1097/TP.0b013e31824612df.
   PubMed Web of Science ®Google Scholar
• Cheng EY, DuBray BJ, Farmer DG. The impact of antibodies and virtual crossmatching on intestinal transplant outcomes. Curr Opin Organ Transplant 2017;22(2):149–154. Apr doi: 10.1097/MOT.0000000000000393.
   PubMed Web of Science ®Google Scholar